Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats

Zhang,Qi; Tan,Yingying; Zhang,Nan; Yao,Fanrong

doi:10.3892/mmr.2014.2708

Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats

Authors:
- Qi Zhang
- Yingying Tan
- Nan Zhang
- Fanrong Yao
View Affiliations

Affiliations: Department of Physiology, Basic Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China, Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
Published online on: October 20, 2014 https://doi.org/10.3892/mmr.2014.2708
Pages: 603-610

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathophysiology of non‑alcoholic fatty liver disease remains to be elucidated, and the currently available treatments are not entirely effective. Polydatin, a stilbenoid compound derived from the rhizome of Polygonum cuspidatum, has previously been demonstrated to possess hepatoprotective effects. The present study aimed to determine the effects of polydatin supplementation on hepatic fat accumulation and injury in rats fed a high‑fat diet. In addition, the mechanisms underlying the protective effects of polydatin were examined. Male Sprague Dawley rats were randomly divided into four groups and received one of four treatment regimes for 12 weeks: Control diet, control diet supplemented with polydatin, high‑fat diet, or high‑fat diet supplemented with polydatin. Polydatin was supplemented in the drinking water at a concentration of 0.3% (wt/vol). The results of the present study showed that long‑term high‑fat feeding resulted in fatty liver in rats, which was manifested by excessive hepatic neutral fat accumulation and elevated plasma alanine aminotransferase and aspartate aminotransferase levels. Polydatin supplementation alleviated the hepatic pathological changes, and attenuated the insulin resistance, as shown by an improved homeostasis model assessment of basal insulin resistance values and a glucose tolerance test. Polydatin supplementation also corrected abnormal leptin and adiponectin levels. Specifically, polydatin supplementation enhanced insulin sensitivity in the liver, as shown by improved insulin receptor substrate 2 expression levels and Akt phosphorylation in the rat liver, following high‑fat diet feeding. The results of the present study suggest that polydatin protects rats against high‑fat feeding‑induced insulin resistance and hepatic steatosis. Polydatin may be an effective hepatoprotective agent and a potential candidate for the prevention of fatty liver disease and insulin resistance.

View Figures

View References

1	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
2	Clark JM, Brancati FL and Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology. 122:1649–1657. 2002. View Article : Google Scholar : PubMed/NCBI
3	Falck-Ytter Y, Younossi ZM, Marchesini G and McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 21:17–26. 2001. View Article : Google Scholar : PubMed/NCBI
4	Guilherme A, Virbasius JV, Puri V and Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 9:367–377. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gariani K, Philippe J and Jornayvaz FR: Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab. 39:16–26. 2013. View Article : Google Scholar : PubMed/NCBI
6	Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37:917–923. 2003. View Article : Google Scholar : PubMed/NCBI
7	Jou J, Choi SS and Diehl AM: Mechanisms of disease progre ssion in nonalcoholic fatty liver disease. Semin Liver Dis. 28:370–379. 2008. View Article : Google Scholar : PubMed/NCBI
8	Tilg H and Moschen AR: Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 19:371–379. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kimura Y: Pharmacological studies on resveratrol. Methods Find Exp Clin Pharmacol. 25:297–310. 2003. View Article : Google Scholar : PubMed/NCBI
10	Xue L: Progress in the pharmacological study of Chinese herbal drug: Polygonum cuspidatum. Zhongguo Zhong Yao Za Zhi. 25:651–653. 2000.(In Chinese).
11	Luper S: A review of plants used in the treatment of liver disease: part two. Altern Med Rev. 4:178–188. 1999.PubMed/NCBI
12	Zhang H, Dou C and Gu F: Advances in the study on pharmacological actions of Polygonum cuspidatum Sieb. et Zucc.: clearing heat and detoxication. Zhong Yao Cai. 26:606–610. 2003.(In Chinese).
13	Zhang H, Yu CH, Jiang YP, et al: Protective effects of polydatin from Polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. PLoS One. 7:e465742012.
14	Ji H, Zhang X, Du Y, Liu H, Li S and Li L: Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 87:50–59. 2012.PubMed/NCBI
15	Du J, Sun LN, Xing WW, et al: Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine. 16:652–658. 2009. View Article : Google Scholar
16	Xing WW, Wu JZ, Jia M, Du J, Zhang H and Qin LP: Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother. 63:457–462. 2009.
17	Zhang J, Tan Y, Yao F and Zhang Q: Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c. Mol Med Rep. 6:815–820. 2012.PubMed/NCBI
18	Brunt EM, Janney CG and Di Bisceglie AM: Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
19	Folch J, Lees M and Sloane Starley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 226:497–509. 1957.PubMed/NCBI
20	Zhang Q, Zhao Y, Zhang DB and Sun LJ: Effect of Sinai san decoction on the development of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 11:1392–1395. 2005. View Article : Google Scholar
21	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar
22	Zhang Q, Yao F, Raizada MK, O’Rourke ST and Sun C: Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 104:1421–1428. 2009. View Article : Google Scholar : PubMed/NCBI
23	Bugianesi E, McCullough AJ and Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
24	Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
25	Youngren JF: Regulation of insulin receptor function. Cell Mol Life Sci. 64:873–891. 2007. View Article : Google Scholar : PubMed/NCBI
26	Khan AH and Pessin JE: Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 45:1475–1483. 2002. View Article : Google Scholar : PubMed/NCBI
27	Le Roith D and Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 24:588–597. 2001.PubMed/NCBI
28	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
29	Wang Q, Somwar R, Bilan PJ, et al: Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol. 19:4008–4018. 1999.PubMed/NCBI
30	Boura-Halfon S and Zick Y: Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 296:E581–E591. 2009. View Article : Google Scholar : PubMed/NCBI
31	Kerouz NJ, Hörsch D, Pons S and Kahn CR: Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest. 100:3164–3172. 1997. View Article : Google Scholar : PubMed/NCBI
32	Shimomura I, Matsuda M, Hammer RE, et al: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 6:77–86. 2000. View Article : Google Scholar : PubMed/NCBI
33	Previs SF, Withers DJ, Ren JM, White MF and Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem. 275:38990–38994. 2000. View Article : Google Scholar : PubMed/NCBI
34	Withers DJ, Gutierrez JS, Towery H, et al: Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:900–904. 1998. View Article : Google Scholar : PubMed/NCBI
35	Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P and Accili D: Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem. 273:17491–17497. 1998. View Article : Google Scholar : PubMed/NCBI
36	Kido Y, Burks DJ, Withers D, et al: Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 105:199–205. 2000. View Article : Google Scholar : PubMed/NCBI
37	Valverde AM, Burks DJ, Fabregat I, et al: Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes. 52:2239–2248. 2003. View Article : Google Scholar : PubMed/NCBI
38	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43:S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
39	Musso G, Gambino R, Durazzo M, et al: Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 42:1175–1183. 2005. View Article : Google Scholar : PubMed/NCBI
40	Gambino R, Cassader M, Pagano G, Durazzo M and Musso G: Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology. 45:1097–1107. 2007. View Article : Google Scholar
41	Wang Z, Yao T, Pini M, Zhou Z, Fantuzzi G and Song Z: Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 298:G634–G642. 2010. View Article : Google Scholar : PubMed/NCBI